{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-273110","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.099997+00:00","generated_at":"2026-06-22T21:59:56.626154+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TherapeuticsMD raises $7M from Rubric Capital; extends debt maturity to Nov 30","bullets":["Issued 7,000 shares of Series A Preferred Stock to Rubric Capital Management for $7M gross proceeds.","Net proceeds to be used for working capital and general corporate purposes.","Financing agreement maturity extended to Nov 30, 2022; lenders received warrants for 125k shares at $0.01.","Warrants have a 10-year term and are exercisable via cashless exercise.","Board and management continue to assess strategic alternatives to strengthen long-term financial position."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-273110","json":"https://secwatch.observer/filing/0001193125-22-273110.json","markdown":"https://secwatch.observer/filing/0001193125-22-273110.md","text":"https://secwatch.observer/filing/0001193125-22-273110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312522273110/0001193125-22-273110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312522273110/d394277d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:59:56.626154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a59ccab97b15bc3e9f144fec19c4ee5297f06838","claim":"TherapeuticsMD, Inc. entered into Subscription Agreement with Rubric Capital Management LP valued at $7 million (effective 2022-10-28).","evidence_excerpt":"On October 28, 2022, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Investor”), pursuant to which the Company issued and sold, in a private placement offering (the “Offering”), 7,000 shares of the Company’s Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), for an aggregate offering price of $7 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312522273110/0001193125-22-273110-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Rubric Capital Management LP"},{"label":"Value","value":"$7 million"},{"label":"Effective","value":"2022-10-28"}],"fact_type":"material_agreement"},{"claim_id":"ab78d93a56dfc263bf232281f00b43770c13faea","claim":"TherapeuticsMD, Inc. entered into Lender Subscription Agreement with the Lenders (effective 2022-10-28).","evidence_excerpt":"on October 28, 2022 the Company issued warrants (the “Lender Warrants”), to the Lenders to purchase an aggregate of 125,000 shares of Common Stock, pursuant to a subscription agreement by and among the Company and the Lenders (the “Lender Subscription Agreement”), and the maturity date of the Financing Agreement was extended to November 30, 2022.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312522273110/0001193125-22-273110-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Lenders"},{"label":"Effective","value":"2022-10-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}